US 10,376,580 B2
Methods of treating cancer with antibody-albumin nanoparticle complexes comprising albumin, trastuzumab, and paclitaxel
Svetomir N. Markovic, Rochester, MN (US); and Wendy K. Nevala, Rochester, MN (US)
Assigned to Mayo Foundation for Medical Education and Research, Rochester, MN (US)
Filed by Mayo Foundation for Medical Education and Research, Rochester, MN (US)
Filed on Jan. 23, 2017, as Appl. No. 15/412,554.
Application 15/412,554 is a continuation of application No. 15/052,623, filed on Feb. 24, 2016.
Application 15/052,623 is a continuation of application No. 14/432,979, previously published as PCT/US2013/062638, filed on Sep. 30, 2013.
Claims priority of provisional application 61/725,293, filed on Nov. 12, 2012.
Claims priority of provisional application 61/708,575, filed on Oct. 1, 2012.
Prior Publication US 2017/0128583 A1, May 11, 2017
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61K 45/06 (2006.01); A61K 31/337 (2006.01); C07K 16/22 (2006.01); C07K 16/32 (2006.01); A61K 33/24 (2019.01); A61K 31/555 (2006.01); A61K 9/00 (2006.01); A61K 9/51 (2006.01); A61K 41/00 (2006.01); C07K 16/30 (2006.01); A61K 47/69 (2017.01); A61K 47/68 (2017.01); A61K 31/282 (2006.01); A61K 47/64 (2017.01); A61K 9/14 (2006.01); B82Y 5/00 (2011.01); A61K 39/00 (2006.01)
CPC A61K 39/39558 (2013.01) [A61K 9/0019 (2013.01); A61K 9/14 (2013.01); A61K 9/51 (2013.01); A61K 9/5169 (2013.01); A61K 31/282 (2013.01); A61K 31/337 (2013.01); A61K 31/555 (2013.01); A61K 33/24 (2013.01); A61K 39/395 (2013.01); A61K 41/0052 (2013.01); A61K 45/06 (2013.01); A61K 47/643 (2017.08); A61K 47/6801 (2017.08); A61K 47/6803 (2017.08); A61K 47/6845 (2017.08); A61K 47/6849 (2017.08); A61K 47/6851 (2017.08); A61K 47/6855 (2017.08); A61K 47/6863 (2017.08); A61K 47/6865 (2017.08); A61K 47/6867 (2017.08); A61K 47/6929 (2017.08); A61K 47/6931 (2017.08); C07K 16/22 (2013.01); C07K 16/2863 (2013.01); C07K 16/2887 (2013.01); C07K 16/2893 (2013.01); C07K 16/3015 (2013.01); C07K 16/32 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); A61K 2039/6056 (2013.01); B82Y 5/00 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 15 Claims
 
1. A method for treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and antibody-albumin nanoparticle complexes, said complexes comprising albumin, an antibody with binding specificity for HER2, and paclitaxel, wherein the nanoparticle complexes have been pre-formed in vitro by mixing aqueous albumin-paclitaxel nanoparticles with the antibody under conditions to form the nanoparticle complexes, such that the nanoparticle complexes have HER2 binding specificity, wherein, the cancer expresses HER2, wherein the antibody is trastuzumab, and wherein the average diameter of greater than 60% of said complexes is between 0.1 μm to 0.95 μm.